Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer

Maria A. Pantaleo, M. Nannini, A. Maleddu, S. Fanti, C. Nanni, S. Boschi, F. Lodi, G. Nicoletti, L. Landuzzi, P. L. Lollini, G. Biasco

Research output: Contribution to journalArticle

Abstract

The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.

Original languageEnglish
Pages (from-to)213-226
Number of pages14
JournalAnnals of Oncology
Volume20
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Epidermal Growth Factor Receptor
Positron-Emission Tomography
Neoplasms
Molecular Imaging
Radioisotopes
Protein-Tyrosine Kinases
Animal Models
Biomarkers
Monoclonal Antibodies
Electrons
Technology
Therapeutics

Keywords

  • Colon cancer
  • Epidermal growth factor receptor (EGFr)
  • Lung cancer
  • Monoclonal antibodies
  • PET
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., ... Biasco, G. (2009). Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 20(2), 213-226. https://doi.org/10.1093/annonc/mdn625

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. / Pantaleo, Maria A.; Nannini, M.; Maleddu, A.; Fanti, S.; Nanni, C.; Boschi, S.; Lodi, F.; Nicoletti, G.; Landuzzi, L.; Lollini, P. L.; Biasco, G.

In: Annals of Oncology, Vol. 20, No. 2, 2009, p. 213-226.

Research output: Contribution to journalArticle

Pantaleo, MA, Nannini, M, Maleddu, A, Fanti, S, Nanni, C, Boschi, S, Lodi, F, Nicoletti, G, Landuzzi, L, Lollini, PL & Biasco, G 2009, 'Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer', Annals of Oncology, vol. 20, no. 2, pp. 213-226. https://doi.org/10.1093/annonc/mdn625
Pantaleo, Maria A. ; Nannini, M. ; Maleddu, A. ; Fanti, S. ; Nanni, C. ; Boschi, S. ; Lodi, F. ; Nicoletti, G. ; Landuzzi, L. ; Lollini, P. L. ; Biasco, G. / Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. In: Annals of Oncology. 2009 ; Vol. 20, No. 2. pp. 213-226.
@article{fec5f5ad2c8c40128a243c2eff27498e,
title = "Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer",
abstract = "The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.",
keywords = "Colon cancer, Epidermal growth factor receptor (EGFr), Lung cancer, Monoclonal antibodies, PET, Tyrosine kinase inhibitors",
author = "Pantaleo, {Maria A.} and M. Nannini and A. Maleddu and S. Fanti and C. Nanni and S. Boschi and F. Lodi and G. Nicoletti and L. Landuzzi and Lollini, {P. L.} and G. Biasco",
year = "2009",
doi = "10.1093/annonc/mdn625",
language = "English",
volume = "20",
pages = "213--226",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer

AU - Pantaleo, Maria A.

AU - Nannini, M.

AU - Maleddu, A.

AU - Fanti, S.

AU - Nanni, C.

AU - Boschi, S.

AU - Lodi, F.

AU - Nicoletti, G.

AU - Landuzzi, L.

AU - Lollini, P. L.

AU - Biasco, G.

PY - 2009

Y1 - 2009

N2 - The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.

AB - The epidermal growth factor receptor (EGFr) is one of the most studied molecules as a target for cancer therapy. Over these last few years, several studies attempting to identify predictive biomarkers of treatment response, such as the receptor status or other molecules related to the downstream signalling pathway, have been conducted. However, from a clinical point of view, the information obtained from ex vivo analyses still has various limitations that may be overcome by the combination with molecular imaging technologies which may provide a noninvasive, global, in vivo evaluation of the molecular tumour background. The aim of this review is to report the preclinical results of all positron emission tomography (PET) tracers synthesized until now for in vivo detection of EGFr in cancer. Two classes of PET compounds have been developed: labelled small molecules such as tyrosine kinase inhibitors and labelled monoclonal antibodies. The in vitro and in vivo results of these PET tracers are very different depending on the chemical properties, positron emission radionuclide, or animal models. As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed.

KW - Colon cancer

KW - Epidermal growth factor receptor (EGFr)

KW - Lung cancer

KW - Monoclonal antibodies

KW - PET

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=60549084533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549084533&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn625

DO - 10.1093/annonc/mdn625

M3 - Article

C2 - 18842614

AN - SCOPUS:60549084533

VL - 20

SP - 213

EP - 226

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -